Citation Impact
Citing Papers
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome
2006
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
2008
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Low Vitamin B12 Levels: An Underestimated Cause Of Minimal Cognitive Impairment And Dementia
2020
Cancer treatment and survivorship statistics, 2022
2022 Standout
Multiple myeloma
2014
Advances in stem cell mobilization
2014
Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis
2000
Proteasome inhibitors in cancer therapy
2017
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
The status of vitamins B6, B12, folate, and of homocysteine in geriatric home residents receiving laxatives or dietary fiber
2010
Acute promyelocytic leukemia current treatment algorithms
2021
Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon?
2000
Sjögren's syndrome
2005 Standout
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
Neutrophils at work
2014 Standout
Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis
2004
Advances in stem cell mobilization
2012
Advances in metal-induced oxidative stress and human disease
2011 Standout
CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome
2005
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
2006
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
2014
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
2014 Standout
Risk factors for thrombophilia in extrahepatic portal vein obstruction†
2005
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives
2014
Hydrogel nanoparticles in drug delivery
2008 Standout
Vascular disorders of the liver # †
2008 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Human FoxP3+ regulatory T cells in systemic autoimmune diseases
2011 StandoutNobel
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis
2004
Killing time for cancer cells
2005
Sensors of the innate immune system: their link to rheumatic diseases
2010 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors
2000
How were new medicines discovered?
2011 Standout
Molecular genetics in acute myeloid leukemia
2010
Oxidative Stress in Cancer
2020 Standout
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
2005 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
2009
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma
2006
Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study
2004
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Multiple cutaneous immunocytoma with secondary anetoderma: a report of two cases
2000
Immune thrombocytopenic purpura in adults
2007
Treatment of Multiple Myeloma: A Comprehensive Review
2009
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
2007
Local application of danazol-loaded hyaluronic acid hydrogel to endometriosis in a rat model
2006
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Inherited Prothrombotic Defects in Budd-Chiari Syndrome and Portal Vein Thrombosis : A Study From North India
2004
An update on cobalamin deficiency in adults
2008
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
2020 Standout
Distúrbios trombofílicos em crianças e adolescentes com trombose da veia porta
2003
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Dietary fibre and fibre-rich by-products of food processing: Characterisation, technological functionality and commercial applications: A review
2010 Standout
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
2011
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2004
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
2010
Lysosomal activity regulatesCaenorhabditis elegansmitochondrial dynamics through vitamin B12 metabolism
2020 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
2007
Inherited Prothrombotic Defects in Budd-Chiari Syndrome and Portal Vein Thrombosis
2004
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1
2016 StandoutNobel
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up
2015
Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.
2000
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal
2009
Chimeric Antigen Receptor Therapy
2018 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer statistics, 2016
2016 Standout
How I treat idiopathic thrombocytopenic purpura (ITP)
2005
How I treat acute promyelocytic leukemia
2009
Cancer statistics, 2015
2015 Standout
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
2008
Cancer treatment and survivorship statistics, 2019
2019 Standout
Molecular Genetics of Acute Lymphoblastic Leukemia
2005
Acute promyelocytic leukemia: from highly fatal to highly curable
2008
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
2013
p53 Antibodies in the sera of patients with various types of cancer: a review.
2000
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Multiple Myeloma
2011 Standout
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)
2007
Works of Frédéric Maloisel being referenced
Oral cobalamin therapy for the treatment of patients with food-cobalamin malabsorption
2001
Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results
2004
Effects of oral crystalline cyanocobalamin 1000 μg/d in the treatment of pernicious anemia: An open-label, prospective study in Ten Patients
2005
Idiopathic thrombocytopenic purpura in elderly patients: A study of 47 cases from a single reference center
2008
Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study
2010
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
2007
Food-cobalamin malabsorption in elderly patients: Clinical manifestations and treatment
2005
Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95
2010
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
2006
Frequent factor II G20210A mutation in idiopathic portal vein thrombosis
1999
Emergence of Unusual Cytogenetic Abnormalities under Interferon-Alpha Therapy in Patients with Chronic Myelogenous Leukemia
1999
Idiosyncratic drug-induced agranulocytosis or acute neutropenia
2008
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials
2003
Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience
2009
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
2003
VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.
2006
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010
Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial
1999
Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group
2006
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
1997
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
1997
Review. Clinical pharmacokinetics of bortezomib.
2007